ESC 365 - Inhibition of Factor XI using a GalNAc-siRNA RBD5049: a novel antithrombotic drug with high potency and long duration

ESC Professional Premium Access

Inhibition of Factor XI using a GalNAc-siRNA RBD5049: a novel antithrombotic drug with high potency and long duration

Session: Oral anticoagulation in patients with venous thromboembolism or left ventricular thrombus

Topic: Anticoagulants

Speaker: Professor L. Gan (Gothenburg, SE)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Professor Li-Ming Gan

Sahlgrenska Academy - University of Gothenburg, Gothenburg (Sweden)

0 follower

6 more presentations in this session

Baseline characteristics and outcomes of extended oral anticoagulant treatment in patients with venous thrombosis: a retrospective cohort study in France

Speaker: Mr R. Subash (Surrey, GB)

Comparative effectiveness and safety of apixaban and low-molecular weight heparin among patients with venous thromboembolism and active cancer in an extended treatment setting

Speaker: Doctor A. Cohen (London, GB)

The effect of DOAC-Stop on lupus anticoagulant testing in patients with pulmonary embolism receiving direct oral anticoagulants

Speaker: Professor A. Undas (Krakow, PL)

Anticoagulant therapy beyond primary treatment among active cancer and non-cancer patients with venous thromboembolism in the United States

Speaker: Doctor A. Cohen (London, GB)

Clinical characteristics and outcomes of super-low-dose edoxaban of 15 mg in patients with acute venous thromboembolism: insight from the COMMAND VTE Registry-2

Speaker: Doctor K. Kaneda (Kyoto, JP)

Access the full session

Oral anticoagulation in patients with venous thromboembolism or left ventricular thrombus

Speakers: Professor L. Gan, Mr R. Subash, Doctor A. Cohen, Professor A. Undas, Doctor A. Cohen...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources